Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs

Journal of Clinical Pharmacology

Volumn 36, Issue 6, 1996, Pages 505-512

  Carabaza, Assumpta ^a   Cabré, Francesc ^a   Rotllan, Elisabet ^a   Gómez, Manel ^a   Gutiérrez, Marta ^a   García, M Lluis̈a ^a   Mauleón, David ^a  

^a Laboratorios Menarini SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FLURBIPROFEN; ICOSANOID; ISOENZYME; KETOPROFEN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; CHIRALITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; RACEMIC MIXTURE; RAT; STEREOCHEMISTRY;

EID: 0030017605     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb05040.x     Document Type: Conference Paper

References (46)

1. Maier JAM, Hla T, Maciag T: Cyclooxygenase is an immediate early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 1990;265:10805-10808.
2. Akarasereenont P, Mitchell JA, Thiemermann C, Vane JR: Lipopolysaccharide induces bovine aortic endothelial cells to synthesize COX, but not nitric oxide synthase: a comparison with macrophages (abstract). Br J Pharmacol 1994;111:3P.
3. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishhop-Baily D, Croxtall J, et al: Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91: 2046-2050.
4. Smith WL, DeWitt DL: Biochemistry of protaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:179-194.
5. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-3232.
6. Seibert K, Zhang Y, Leahy KM, Hauser SD, Masferrer JL, Perkins W, et al: Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-12017.
7. Boynton CS, Dick CF, Mayor GH: NSAIDs: an overview. J Clin Pharmacol 1988;28:512-517.
8. Vane JR, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
9. Matsuda K, Tanaka Y, Ushiyama S, Ohnishis K, Yamazaki M: Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate (CS-600), a new anti-inflammatory drug, and its active metabolite in vitro and in vivo. Biochem Pharmacol 1984;15:2473-2478.
10. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ: Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflamm Res 1995;44:253-257.
11. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al: NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-110.
12. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygonase (COX-2) activity in vitro. Prostaglandins 1994;47:55-59.
13. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-1537.
14. Mitchell JA, Akarasereenont P, Thiermermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-11697.
15. Muller N, Payan E, Lapicque F, Bannwarth B, Netter P: Pharmacological aspects of chiral nonsteroidal antiinflammatory drugs. Fundam Clin Pharmacol 1990;4:617-634.
16. Wechter WJ, Loughhead DG, Reischer RJ, VanGiessen GJ, Kaiser DG: Enzymatic inversion at saturated carbon: nature and mechanism of the inversion of R(-) p-iso-butyl hydratropic acid. Biochem Biophys Res Commun 1974;61:833-837.
17. Wechter WJ: Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 1994;34:1036-1042.
18. Ku EC, Wasvary JM: Inhibition of prostaglandin synthase by pirprofen: studies with sheep seminal vesicle enzyme. Biochim Biophys Acta 1975;384:360-368.
19. Gaut ZN, Baruth H, Randall LO, Ashley C, Paulsrud JR: Stereoisomeric relationship among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins 1975;10:59-66.
20. Buttinoni A, Ferrari M, Colombo M, Ceserani R: Biological activity of indoprofen and its optical isomers. J Pharm Pharmacol 1983;35:603-604.
21. Guzman A, Yuste F, Toscano RA, Young JM, van Horn AR, Muchowski JM: Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-α]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac. J Med Chem 1986;29:589-591.
22. Yamaguchi T, Hirose K, Nakamura Y, Sugeno K: The inhibitory activities of 480156-S and its related compounds on prostaglandin synthetase. Folia Pharmacol Jpn 1987;90:295-302.
23. Cerletti C, Manarini S, Colombo M, Tavani A: The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen. J Pharm Pharmacol 1990;42:885-887.
24. Patrignani P, Volpi D, Ferrario R, Romanzini L, di Somma M, Patrono C: Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. Eur J Pharmacol 1990;191:83-88.
25. Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA: Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclooxygenase inhibition: relationship between the inhibition of thromboxane synthesis and the plasma unbound concentration of S(+)-ibuprofen. Br J Clin Pharmacol 1991;31:131-138.
26. Peskar BM, Kulge S, Peskar BA, Soglowek SM, Brune K: Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo. Prostoglandins 1991;42:515-531.
27. Hayball PJ, Nation RL, Bochner F: Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992;4:484-487.
28. Suesa N, Fernández MF, Gutiérrez M, Rufat MJ, Rotllan E, Calvo L, et al: Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993;5: 589-595.
29. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, et al: Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methane sulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 1995;116:2429-2434.
30. Lukas H, Schuster O, Gunther R. Separation of mixtures of enantiomers of arylpropionic acids. German Patent DE 3824353 A1. Frankfurt, Germany: PAZ Frankfurt, 1990.
31. Palomer A, Cabré M, Ginesta J, Mauleon D, Carganico G: Resolution of rac-ketoprofen esters by enzimatic reactions in organic media. Chirality 1993;5:320-328.
32. Patrignani P, Panara M, Greco A, Fusco O, Natoli C, Iacobelli S, et al: Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-1712.
33. 2 production in healthy subjects. Thromb Res 1980;17:317-327.
34. Klein T, Nüsing RM, Pfeilschifter J, Ullrich V: Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-1610.
35. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21(suppl 97):77-89.
36. 2 synthase-1. Nature 1994;367: 243-249.
37. Shimokawa T, Kulmacz RJ, DeWitt DL, Smith WL: Tyrosine 385 of prostaglandin synthase is required for cyclooxygenase catalysis. J Biol Chem 1992;265:20073-20076.
38. Xie W, Robertson DL, Simmons DL: Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-265.
39. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL: Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934.
40. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993;268:6610-6614.
41. Lapicque F, Muller N, Payan E, Dubois N, Netter P: Protein binding and stereoselectivity of Nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1993;25:115-125.
42. Villanueva M, Heckenberger R, Strobach H, Palmér M, Schrör K: Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Clin Pharmacol 1993;35:235-242.
43. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al: Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 1994;91:11202-11206.
44. Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995;306:247-251.
45. Wennogle LP, Liang H, Quintavalla JC, Bowen BR, Wasvary J, Miller DB, et al: Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett 1995;371:315-329.
46. Loll PJ, Garavito RM: The isoforms of cyclooxygenase: structure and fuction. Exp Opin Invest Drugs 1994;3:1171-1180.